Trends and developments in liposome drug delivery systems

被引:708
作者
Lian, T [1 ]
Ho, RJY [1 ]
机构
[1] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
关键词
D O I
10.1002/jps.1023
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Since the discovery of liposomes or lipid vesicles derived from self-forming enclosed lipid bilayers upon hydration, liposome drug delivery systems have played a significant role in formulation of potent drugs to improve therapeutics. Currently, most of these liposome formulations are designed to reduce toxicity and to some extent increase accumulation at the target site(s) in a number of clinical applications. The current pharmaceutical preparations of liposome-based therapeutics stem from our understanding of lipid-drug interactions and liposome disposition mechanisms including the inhibition of rapid clearance of liposomes by controlling size, charge, and surface hydration. The insight gained from clinical use of liposome drug delivery systems can now be integrated to design liposomes targeted to tissues and cells with or without expression of target recognition molecules on liposome membranes. Enhanced safety and heightened efficacy have been achieved for a wide range of drug classes, including antitumor agents, antivirals, antifungals, antimicrobials, vaccines, and gene therapeutics. Additional refinements of biomembrane sensors and liposome delivery systems that are effective in the presence of other membrane-bound proteins in vivo may permit selective delivery of therapeutic compounds to selected intracellular target areas. (C) 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 90:667-680, 2001.
引用
收藏
页码:667 / 680
页数:14
相关论文
共 91 条
[1]   PHARMACOKINETICS OF LONG-CIRCULATING LIPOSOMES [J].
ALLEN, TM ;
HANSEN, CB ;
DEMENEZES, DEL .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (2-3) :267-284
[2]   LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].
ALLEN, TM ;
HANSEN, C ;
MARTIN, F ;
REDEMANN, C ;
YAUYOUNG, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36
[3]  
Alving CR, 1992, J Liposome Res, V2, P383, DOI [10.3109/08982109209010216, DOI 10.3109/08982109209010216]
[4]   Immunogenicity and protectivity of a new liposomal hepatitis A vaccine [J].
Ambrosch, F ;
Wiedermann, G ;
Jonas, S ;
Althaus, B ;
Finkel, B ;
Gluck, R ;
Herzog, C .
VACCINE, 1997, 15 (11) :1209-1213
[5]  
ATON EW, 1999, LANCET, V353, P947
[6]   LIPOSOMES - THE BABRAHAM CONNECTION [J].
BANGHAM, AD .
CHEMISTRY AND PHYSICS OF LIPIDS, 1993, 64 (1-3) :275-285
[7]  
Beauchamp C, 1984, Adv Exp Med Biol, V165 Pt A, P47
[8]  
Bendas G, 1998, Pharm Acta Helv, V73, P19, DOI 10.1016/S0031-6865(97)00043-5
[9]   Lipid association increases the potency against primary medulloblastoma cells and systemic exposure of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats [J].
Bethune, C ;
Blum, A ;
Geyer, JR ;
Silber, JR ;
Ho, RJY .
PHARMACEUTICAL RESEARCH, 1999, 16 (06) :896-903
[10]   MOLECULAR MECHANISM OF THE LIPID VESICLE LONGEVITY INVIVO [J].
BLUME, G ;
CEVC, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1146 (02) :157-168